Rupee At 63.70 to Dampen IT, Pharma Performance

Posted By:
Subscribe to GoodReturns

The rupee gained a staggering 37 paise following the RBI credit policy, wherein repo rates were cut by 25 basis points. The strong rupee is likely to dampen the performance of IT and Pharma companies. Both these sectors are facing a downturn and performance is teetering. On Wednesday, Lupin, India's second largest pharma company reported a sharp downturn in performance in the US.

Rupee At 63.70 to Dampen IT, Pharma Performance
IT companies like TCS and Infosys are already stumbling and there are signs of a downturn. If the rupee gains further it would do little to help exporters, especially from the pharma, IT and textile space.

The rupee has now seen the best closing for since July 22, 2015, when it had ended at 63.58 against the US dollar. Check currency rates here

On Wednesday, the RBI may have bought dollars towards the fag-end which may have prompted the rupee to end at 63.70.

Analysts believe that there may not be too much of an upside as the Reserve Bank of India may continue to mop-up dollars. the sharp gains seen in the rupee may also be on account of the RBI policy, where the central bank cut interest rates after 10 months.

Read more about: infosys, tcs, pharma
Story first published: Thursday, August 3, 2017, 8:08 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


Get Latest News alerts from Goodreturns